Travere Therapeutics, Inc. (TVTX) Financials

TVTX Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 555.2 million 456.5 million
Dec. 31, 2025 605.2 million 490.4 million
Sept. 30, 2025 538.6 million 465.0 million
June 30, 2025 555.3 million 522.6 million

TVTX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -62.5 million 16.1 million
Dec. 31, 2025 61.1 million 11.5 million
Sept. 30, 2025 14.2 million 11.3 million
June 30, 2025 4.7 million 10.6 million

TVTX Net Income

No data available :(

TVTX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 264.7 million 321.6 million 15.6 million
Dec. 31, 2025 322.8 million 322.9 million 11.1 million
Sept. 30, 2025 254.5 million 324.0 million 18.4 million
June 30, 2025 319.5 million 311.0 million 19.7 million

TVTX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 91.9 million
Dec. 31, 2025 90.3 million
Sept. 30, 2025 102.6 million
June 30, 2025 88.9 million

TVTX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 22.2 million 57.1 million 80.3 million -
Dec. 31, 2025 375000 57.9 million 101.7 million -
Sept. 30, 2025 140000 51.9 million 86.5 million -
June 30, 2025 235000 49.4 million 76.2 million -

TVTX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 127.2 million 26.8 million
Dec. 31, 2025 129.7 million 2.6 million
Sept. 30, 2025 164.9 million 1.6 million
June 30, 2025 114.4 million 1.5 million

TVTX Revenue by Segment
Graph available only for paid members. Upgrade to see it.

TVTX

Price: $53.80

52 week price:
13.88
53.80

Earnings Per Share: -0.50 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 1.1 million

Market Capitalization: 4.3 billion

Links: